Ocular surface reconstruction with BrightMEM corneal allografts, a foundation for durable epithelial regeneration
On-demand training
Surgeons can access complete BrightMEM product details including a white paper, case study, scientific background, surgical instruction, surgery video and more through Eversight Academy.
BrightMEM anterior keratoplasty (DMAK) is a surgical procedure in which a BrightMEM corneal allograft is transplanted onto the ocular surface to serve as an optimized substrate.
This novel corneal allograft promotes regeneration of the corneal epithelium. BrightMEM is made from Descemet's membrane, which serves as an optimized substrate for protecting the stroma from degradation and promoting regeneration of the corneal epithelium.
BrightMEM expresses proteins that stimulate limbal stem cell growth while resisting degradation. In preclinical studies, BrightMEM supported limbal stem cell expansion and maintained a population of stem cells in the basal corneal epithelium.
BrightMEM offers hope as a durable solution for patients with severe corneal disorders through its regenerative properties.
"I have had the privilege of working with Eversight for nearly 16 years and their commitment to quality of care and support for donor families, the surgeon and patients is unparalleled. I know when I use Eversight services, my patients are in the best of hands."
